Fractyl Health has received European approval to start Phase 1/2 trials for its new gene therapy candidate, RJVA-001. This innovative treatment aims to help your body produce GLP-1, a hormone that plays a crucial role in regulating appetite and blood sugar levels, after just one administration. Patient enrollment for the trial is set to begin on June 1, with dosing expected later this year. This development is part of a broader trend in the pharmaceutical industry, which is exploring various approaches to weight management and metabolic health, including one-time gene therapies and oral medications.

For those looking to age well and maintain a healthy weight, these advancements could be significant. GLP-1 therapies are gaining traction for their potential to support weight loss and improve metabolic health. The approval of oral medications like Wegovy Pill and Foundayo suggests that more accessible treatment options are becoming available. In fact, Wegovy Pill reported impressive sales and prescriptions shortly after its launch, indicating a strong interest in these therapies among healthcare providers and patients alike.

The research is still in its early stages, particularly for RJVA-001, which is yet to prove its effectiveness in humans. While there are promising results from other GLP-1 therapies, such as Eli Lilly’s Retatrutide and Novo Nordisk’s CagriSema, which have shown significant weight loss in trials, it’s important to approach these developments with cautious optimism. As these treatments evolve, they may offer new ways to support your health and longevity.

Source: longevity.technology